Akums Drugs IPO

About Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited, established in 2004, is a leading pharmaceutical contract development and manufacturing organization (CDMO) providing a comprehensive range of products and services in India and internationally.

The company offers end-to-end solutions for product development, manufacturing, research and development (R&D) of formulations, regulatory dossier preparation, and submission, along with other testing services. Akums is also involved in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs).

As a CDMO, Akums produces a variety of dosage forms, including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections, and gummy bears. The company has commercialised 4,025 formulations in over 60 dosage forms and, in 2023, manufactured formulations for 26 of India's top 30 pharmaceutical companies by revenue. Akums operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually as of September 30, 2023.

Plans for expansion include two additional production units set to be commissioned in FY 2025. Some of Akums' facilities are accredited by global regulatory bodies such as EU-GMP, WHO-GMP, and US NSF. The company employs 16,463 individuals, comprising 7,211 full-time and 9,252 contract employees, as of September 30, 2023.

Industry Outlook:

1. The Indian pharmaceutical industry, valued at $50 billion, is projected to reach $65 billion by 2024 and $130 billion by 2030, demonstrating rapid growth.
2. India supplies over 50% of Africa’s generics, 40% of the US's generic demand, and 25% of all medicines in the UK, underscoring its global pharmaceutical dominance.

Akums Drugs and Pharmaceuticals Limited IPO Objectives

The company plans to allocate the net proceeds from the issuance to the following purposes:

1. Repayment/ prepayment of indebtedness of the company and its subsidiaries.
2. Repayment/ prepayment of indebtedness of the Subsidiaries, namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited
3. Funding incremental working capital requirements of the company.
4. Pursuing inorganic growth initiatives through acquisitions.
5. General corporate purposes.

Peer Details

The following are the listed peer companies of Akums Drugs and Pharmaceuticals in India:

1. Divi's Laboratories Limited
2. Suven Pharma Limited
3. Gland Pharma Limited
4. Torrent Pharma Limited
5. Alkem Laboratories Limited
6. Eris Lifesciences Limited
7. JB Chemicals Limited
8. Mankind Pharma Limited
9. Innova Captab Limited

How To Check the Allotment Status of the Akums Drugs and Pharmaceuticals Limited IPO?

Steps to check IPO allotment status on Angel One’s app:

• Log in to the Angel One app.
• Go to the individual order details page of the IPO that you had applied for.
• Check the IPO allotment status. As such, Angel One will notify you of your IPO allotment status via push notification, email and SMS.

Contact Details of Akums Drugs and Pharmaceuticals Limited

Registered office: 304, Mohan Place, LSC Saraswati Vihar, Delhi 110 034, India.

Phone: + 91 11 6904 1000

E-mail: cs@akums.net